Epigenetic changes are widespread in melanoma and contribute to the pathogenic biology of this disease. In the present study we show that I-BET151, which belongs to a new class of drugs that target the BET family of epigenetic "reader" proteins, inhibits melanoma growth in vivo and induced variable degrees of apoptosis in a panel of melanoma cells. Apoptosis was caspase dependent and associated with G1 cell cycle arrest. All melanoma cells tested had increased levels of the BH3 pro-apoptotic protein BIM which appeared to be regulated by the BRD2 BET protein and to some extent BRD3. In contrast knockdown experiments indicated that inhibition of BRD4 was associated with decreased levels of BIM. Apoptosis was dependent on BIM in some but not all cell lines indicating that other factors were determinants of apoptosis such as down regulation of anti-apoptotic proteins revealed in gene expression arrays. G1 cell cycle arrest appeared to be mediated by p21 and resulted from inhibition of the BRD4 protein. The activity of BET protein inhibitors appears independent of BRAF and NRAS mutational status of melanoma and further studies to assess their therapeutic role in melanoma are warranted.
Introduction
Although there have been major advances in the treatment of melanoma based on the use of targeted therapies (Jang and Atkins, 2013; Sullivan et al., 2013) and immunotherapy with monoclonal antibodies against checkpoint inhibitors (Riley, 2013; Robert et al., 2013 ) the disease remains incurable in the majority of patients. We have reviewed elsewhere some of the evidence that epigenetic changes underlie many aspects of melanoma biology (Lai et al., 2012b) including resistance to targeted therapies, melanoma invasiveness and regulation of microphthalmia-associated transcription factor (MITF) .
These and studies by others indicate that dysregulation of chromatin is a frequent event in melanoma (Becker et al., 2009; Hodis et al., 2012; van den Hurk et al., 2012) and other cancers (Blair and Yan, 2012; Fullgrabe et al., 2011) yet the role of new therapies targeting epigenetic changes in melanoma remains under explored.
Chromatin regulation is largely due to methylation of DNA or to modification of histones.
Histones are modified by several protein groups which act either as "writers" by adding acetyl, methyl or other groups to histones or "erasers" which remove such groups and included histone deacetylases (HDACs) and demethylases. The writers and erasers establish what is referred to as a "histone code" that is "read" by a third family of proteins that recognize the histone code and act to focus large protein complexes to those sites (Arrowsmith et al., 2012; . These protein complexes or modules appear characteristic of the gene expression status such as repression or activation and the particular tissues involved (Ernst and Kellis, 2012; Ram et al., 2011) . For example, mapping of just nine acetyl and methyl marks was found to define 15 chromatin states relating to transcriptional activity of surrounding genes (Arrowsmith et al., 2012) . Particular interest has focused on the development of inhibitors against a highly conserved class of "reader" proteins referred to as bromodomain and extraterminal (BET) proteins. The BET family, which consists of BRD2, BRD3, BRD4 and the testis specific BRDT, have two bromodomains in the N terminal region which bind to acetylated lysines in histones and a Cterminal (CT) region which binds to transcription elongation factors (TEFs) (Filippakopoulos et al., 2012) . The bromodomains act to target protein complexes to particular chromosomal regions involved in gene transcription and act as coregulators of transcription (Belkina and Denis, 2012; Prinjha et al., 2012) . The first BET inhibitor JQ1, inhibited the growth of rare NUT midline carcinomas that are caused by fusion of the BRD4 BET protein with the nuclear protein of testis (NUT) protein (Filippakopoulos et al., 2010) . Related BET protein inhibitors I-BET151 and I-BET762 have been described by Nicodeme et al (2010) (Nicodeme et al., 2010) and shown to inhibit BET proteins BRD2, BRD3 and BRD4. Subsequent studies have shown that BRD4 appears to be the target of these drugs in AML (Zuber et al., 2011) , neuroblastoma (Puissant et al., 2013a) and melanoma (Segura et al., 2013b) . The effects on AML and of other c-Myc dependent tumors were believed to be largely due to down regulation of c-Myc (Delmore et al., 2011; Mertz et al., 2011) .
We and others have shown that pan-HDAC inhibitors can induce apoptosis in melanoma that is associated with upregulation of BIM, BAX and BIK and down regulation of Bcl-XL and XIAP (Gillespie et al., 2006; Lai et al., 2012b; Zhang et al., 2004) . Such inhibitors were also strongly synergistic with selective BRAF inhibitors in induction of apoptosis of melanoma (Hersey et al., 2010) . In the present study we examined the influence of the BET protein inhibitor I-BET151 on the survival of a series of human melanoma cells including short term melanoma cultures established from patients that relapsed while on treatment with the BRAF inhibitor vemurafenib.
We report that I-BET 151 induces cell cycle arrest and apoptosis in melanoma and inhibits melanoma cell survival. These effects are due at least in part, to the inhibition of BET-mediated 5 suppression of the cyclin dependent kinase inhibitor p21 and BET-mediated activation of the pro-apoptotic BH3 only protein BIM.
Results

I-BET151 induces melanoma cell death and cell cycle arrest and inhibits melanoma growth in vivo
To determine the effect of I-BET151 on growth of melanoma cells we examined the sensitivity of Me1007 melanoma cells over a range of drug doses and culture periods. As shown in Figure   1A , growth inhibition was seen after 48-72 hours at both 10µM and 100 µM of drug and also after 24h at the higher concentration. In view of this and pharmokinetic studies showing attainable in vivo blood concentrations of at least 10µM for 12 hours following dosing (Dawson et al., 2011) , subsequent studies were carried out at the lower 10µM I-BET151 concentration after 48 hours treatment unless shown otherwise. I-BET151 also inhibited the growth of other melanoma cell lines to various degrees (Figure S1a ).
To assess if I-BET151 also had activity in vivo, we tested the effects of I-BET151 in NOD/SCID mice with melanoma xenografts. Xenografts were established by injecting Patient-1-post cells in the flank of NOD/SCID mice and after tumors had established the mice were given 25mg/kg I-BET151 or vehicle by once daily oral gavage for 7 days followed by a 2 day break before treatment was recommenced at 20mg/kg. This schedule was well tolerated with mean body weight not exceeding 10 % ( Figure S1b ). I-BET151 treatment significantly inhibited Patient-1-post tumor growth by 56 % on day 15 (p<0.001, t-test) (Figure 1B) .
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We then assessed if I-BET151 could induce apoptosis or inhibit cell cycle in a panel of melanoma cell lines. Little apoptosis was observed after 24h of I-BET151 treatment (data not shown) however apoptosis was observed in some lines after 48 h ( Figure 1C ), suggesting relatively slow kinetics of apoptosis induction. Of the continuous melanoma cell lines, the NRAS mutant cell line (Mel-RM) and the NRAS/BRAF wild type line (Me1007) were sensitive to I-BET151 whereas the NRAS mutant/BRAF wild type (Mel-JD) and NRAS wild type/BRAF mutant cell lines (SK-Mel-28, Mel-RMU) were relatively insensitive to this drug (Figure 1C and supplementary Figure S2) . Apoptosis was induced at high levels in the pretreatment lines from patient 3 and less so in the pretreatment line from patient 1. Both post relapse lines from these patients were relatively resistant in apoptosis assays. Normal neonatal human epidermal melanocytes (HEMn) and dermal fibroblasts did not undergo cell death with I-BET151 treatment ( Figure 1C ). G1 arrest was induced by I-BET151 and was more evident in the pretreatment primary cultures from patient 1 and 3 than the corresponding post-relapse lines (Figure 1D and supplementary Figure S3) . A reduction in cells entering S-phase and replicating DNA was confirmed using BrdU/7-AAD dual staining in Patient-1-pre and Patient-3-pre cells, confirming G1 arrest (supplementary Figure S4A ). Varied levels of G1 arrest were documented in the continuous cell lines ranging from a prominent arrest (Mel-RM) to negligible levels in Mel-RMU. There was relatively little G1 arrest in the sensitive Me1007, although S-phase inhibition and an increase in G2/M population was observed. A decrease in S-phase was observed in all cell lines (p-value <0.05, Welch's t-test).
I-BET151 upregulates the pro-apoptotic BH3 protein BIM but not other BH3 proteins
To investigate the mechanism of I-BET151 induced apoptosis we carried out western blots on a range of pro and anti-apoptotic proteins in five of the melanoma cell lines. As shown in Figure   2A , after 48 hours of I-BET151 treatment there was consistent upregulation of BIM EL and its isoforms and downregulation of Puma, Bik, tBID and BMF to varying degrees in the different cell lines. SK-Mel-28 had high levels of BIM in the untreated and treated samples. There were minimal or variable changes in BAX, BAK and NOXA. Amongst the anti-apoptotic proteins there were consistent decreases in the XIAP inhibitor of apoptosis (IAP) protein, small increases in MCL-1 levels and small decreases in Bcl-2 and Bcl-XL. The increases in BIM (particularly the short isoform) and decreases in the anti-apoptotic proteins were most evident in the two relatively sensitive lines, Me1007 and Mel-RM and this coincided with PARP cleavage and presence of cleaved caspase 3 (Figure 2A ). Similar changes were seen in the western blots of cell lines from patients 1 and 3 (supplementary Figure S4B ).
Apoptosis was caspase dependent and mediated in part by BIM
We investigated whether apoptosis was caspase dependent by pre-treating cells with the pancaspase inhibitor Q-VD-OPh (Kuzelova et al., 2011) . As shown in Figure 2B , caspase inhibition almost completely prevented I-BET151 mediated apoptosis in the three most sensitive cell lines.
TRAIL induced apoptosis was used as a positive control and is known to be caspase driven.
Previous studies have shown that Me1007 cells lack caspase 8 and are resistant to TRAIL . Caspase dependent apoptosis can occur via the intrinsic apoptotic pathway which involves depolarization of mitochondria, controlled by changes in the Bcl-2 8 family members, including BIM. Measurement of mitochondrial outer membrane potential by JC-1 showed I-BET151 treatment lead to depolarized mitochondria in Me1007, Mel-RM and Patient-3-pre cells ( Figure 2C ).
BIM is a pro-apoptotic member of the Bcl-2 family which controls depolarization of mitochondria, leading to apoptosis via caspase dependent and independent mechanisms. The increase in BIM protein levels (Figure 2A ) appeared to be due to transcriptional upregulation as shown by the increase in mRNA levels of BIM 6 hours after I-BET151 treatment ( Figure 2D ).
This was also evident in the melanocyte and fibroblast lines.
To further investigate the role of BIM in I-BET151 induced apoptosis, BIM was knocked down by siRNA in the sensitive Me1007 cells and patient-3-pre cells. As shown in Figure 2E 
I-BET151 induces cell cycle arrest by upregulation of p21
We examined known cell cycle regulatory genes after culture of the melanoma lines in 10µM I-BET151 for 48 hrs. As shown in Figure 3A and B there was a consistent increase in p21 and Cyclin D in the continuous lines and p21 in the primary patient derived lines. There was also an increase in p27 and p53 in the latter lines. p53 increased in all the lines except in Mel-RM and patient-3-post line. Bromodomain target c-myc (Dawson et al., 2011; Puissant et al., 2013a) was not detectably altered in our panel of melanoma cells.
To further investigate the role of p21 we knocked down its expression by siRNA ( Figure 3D ).
This diminished the G1 arrest induced by I-BET151 in the pretreatment cell lines from patient 1 and 3 ( Figure 3C ), consistent with the dominant role of this CDK inhibitor in regulating G1-S progression.
BRD2 proteins appear responsible for suppression of BIM whereas BRD4 suppresses
CDKN1A (p21)
To determine which BRD proteins were involved in regulation of BIM and p21 we knocked down the individual BRD proteins using two separate siRNAs for each gene. As shown in Figure   4A and 4B, BRD3 and BRD4 transcript levels were effectively suppressed (60-80%) by the targeted siRNAs in the Me1007 and Patient-3-pre cell lines. BRD2 message was also knocked down by more than 50%, except by BRD2 siRNA#1 in the patient-3-pre treatment line.
As shown in Figure 4C ,D knockdown of BRD2 resulted in increased expression of BIM (BCL2L11) in both Me1007 and Patient-3-pre cells, although the second BRD2 silencer only caused a small, but statistically significant increase in BIM in Me1007 ( Figure 4C ). In contrast, knockdown of BRD4 by both silencing molecules resulted in a marked decrease in expression of the BIM gene in both melanoma lines. Ablation of BRD3 did not affect BIM mRNA levels.
These results were reflected at the protein level as determined by western blot ( Figure S5B ).
Knockdown of BRD proteins increases apoptosis and cell cycle arrest
Although there was a clear difference in effects of siRNA for BRD2 and 3 compared to BRD4 on mRNA for BIM, knockdown of each of the three genes increased apoptosis in the patient-3-pre line, while only BRD2 siRNA increased apoptosis in Me1007 (Figure 4C, D) . The fact that BRD4 knockdown can cause apoptosis in patient-3-pre cells while reducing BIM levels suggest that BRD4 normally suppresses other mediators of apoptosis or upregulates anti-apoptotic proteins like Bcl2, which was slightly reduced following BRD4 ablation ( Figure S5B ) .
Both siRNAs against BRD4 produced G1 cell cycle arrest to varying extent in both Me1007 and the line from patient 3 ( Figure 4E , F) whereas only one each of the siRNA pairs against BRD2 and BRD3 produced G1 arrest in the Me1007 line ( Figure 4E ).
I-BET151 upregulates pro-apoptotic and cell cycle arrest genes in melanoma cells
We used gene expression microarrays to examine changes in global gene expression 6 and 24 hours after exposure of the cell lines from patient 1 and 3 to I-BET151. Using these data, we first examined genes relating specifically to inducing apoptosis. Figure 5 shows genes with expression that varied by more than 50% following I-BET151 treatment. Genes are grouped according to whether they were pro (red) or anti-apoptotic (green) according to GO gene ontology (GO terms 0043066 or 0010942) or have been associated with either role (blue bars).
All four cell lines showed increased gene expression of the pro-apoptotic proteins Noxa, DAPK, RhoB and Foxo3, 6h after I-BET151 treatment. PMAIP1 (Noxa) is well described as a BH3 protein induced by p53. STK17B (Death associated protein kinase DAPK) was reported previously as a hypermethylated gene in melanoma (Hoon et al., 2004) and to be involved in UV 11 induced apoptosis (Kuwahara et al., 2006) . RhoB is considered to have a tumor suppressive role and to be down regulated by the RAS/Akt pathway (Jiang et al., 2004) . The Foxo3 transcription factor upregulates BIM (Gillings et al., 2009 ). There were no major differences between the pretreatment line from patient 3 that underwent apoptosis and the resistant line in this patient which may suggest the induction of cell death is dependent on the balance between pro and anti apoptotic gene expression in each line. Full data is in Sup Table 1f-g.
We used the LimmaGP tool in GenePattern to identify genes differentially expressed after I-BET151 treatment. Gene set enrichment analysis (GSEA) identified a variety of gene sets down regulated, including those relating to ribosomes, hormone receptor binding, mitosis and NF-kB, while there was a mixture of upregulated genesets (Sup Table 1c ). After 24 hours, the overwhelming number of down-regulated genesets related to mitosis and cell cycle (Sup Table   1d ). Downregulated genes within the most significantly decreased geneset -Cell_Cycle_Process included cyclin A2, CDK4, CDK2 and aurora kinase (Sup Table 1e ).
We also noted that many genes transcribing histone genes were upregulated by I-BET151 treatment (Sub Table 1 ). Histone gene transcription is normally tightly regulated, and alterations in histone levels can perturb cell cycle and lead to apoptosis. These results require validation and further investigation.
Discussion
The above studies have identified a number of potentially important anticancer effects of I-BET151 against melanoma cells that may be exploited in future preclinical studies. All melanoma lines tested responded to I-BET151 with an altered cell cycle or survival profile. This involved induction of G1 cell cycle arrest, mediated in part by the upregulation of p21 as shown in western blots and by inhibition of G1 arrest when p21 was downregulated by siRNA. A subset of melanoma cells also underwent caspase-dependent apoptosis in response to I-BET151 and this was associated with loss of mitochondrial outer membrane potential. Apoptosis was associated with upregulation of the BH3 pro-apoptotic BIM protein in the majority of cell lines and siRNA knockdown of BIM confirmed it played a role in inducing apoptosis. A number of other changes in pro and anti apoptotic proteins were detected in western blots and further studies are needed to give a more complete understanding of the changes responsible for induction of apoptosis.
Successful development of treatments based on epigenetic modifiers have largely been focused on hematologic malignancies and with relatively non-specific pan HDAC inhibitors such as vorinostat and panobinostat. Our preclinical studies have also shown strong synergy between HDAC inhibitors and selective BRAF inhibitors (Hersey et al., 2010; Lai et al., 2012b) and recent reports suggest the benefit of targeting epigenetic modulators in BRAFi resistant melanoma (Johannessen et al., 2013) . The BET protein inhibitors like I-BET151 and JQ1 are more restricted in their action and competitively inhibit BET protein binding to acetylated histones. They have shown selectivity for hematologic malignancies driven by c-Myc and the rare NUT midline carcinoma. The present study adds to information about non hematologic cancers that may be responsive to the BET protein inhibitors such as N-Myc dependent neuroblastoma (Puissant et al., 2013b) , glioma (Cheng et al., 2013) , lung carcinoma (Lockwood et al., 2012) and melanoma (Segura et al., 2013b) . In the case of lung carcinoma sensitivity to the BET protein inhibitor appeared to be based on downregulation of the oncogenic transcription 13 factor FOSL1 which could be reproduced by knockdown of BRD4 (Lockwood et al., 2012) . A previous study on human melanoma lines exposed to the BET protein inhibitor MS417 did however find downregulation of c-Myc as well as ERK and SKP2 (Segura et al., 2013b) . In studies on gliomas there was no association between sensitivity to JQ1 and core signaling pathways such as Akt, p53 or Rb pathways resulting from mutations in key pathway proteins.
This also appeared to be the case in the present study on melanoma but further analysis is needed to confirm this.
One of the most consistent effects of I-BET 151 was upregulation of the BH3 pro-apoptotic Bcl-2 family protein BIM, even though a range of other BH3 proteins such as Noxa and Puma were unchanged or down regulated in the western blot studies. The predominant isoforms of BIM (EL, L and S) can bind all anti-apoptotic members of the Bcl-2 family and have been shown to be potent induces of apoptosis in melanoma (Berger et al., 2014; Plotz et al., 2013) . In our studies, there did not appear to be differential expression of the different BIM isoforms, with all being changed by the same extent. The increase in BIM was seen at the mRNA level suggesting that upregulation was mediated transcriptionally rather than by inhibition of degradation through the proteasome that is known to be important in the biology of BIM (Faber et al., 2012; Gillings et al., 2009) . BIM can be transcriptionally regulated by a number of transcription factors such as E2F1, FOXO3a, CHOP-C during endoplasmic stress, c-Myc, Rel-A and c-Jun (reviewed in (Pinon et al., 2008) . Phosphorylation of BIM by JNK was reported to result in its release from microtubules but this would not be expected to change overall protein levels (Gillings et al., 2009) . As reported elsewhere (Gallagher et al submitted) I-BET151 is a strong inhibitor of NFkB in melanoma. It was also reported that NF-kB was able to suppress BIM in response to a 14 number of stimuli (Banerjee et al., 2008; Busuttil et al., 2010; Wang et al., 2008) but inhibition of NF-kB by BMS345541 (Yang et al., 2006) in our studies did not upregulate BIM and did not affect induction of BIM by I-BET151 (data not shown). This suggests that supression of NF-kB alone is not responsible for the observed increase in BIM following I-BET151 treatment. Gene expression array studies identified strong upregulation of FOXO3 and down regulation of E2F2 by I-BET151 and ongoing studies suggest these may be the main transcription factors involved in regulation of BIM. There were neglible changes in CHOP C/EBP and c-Jun in our cells.
Although BIM was increased in all the melanoma lines tested apoptosis was cell line dependent.
This may reflect inhibition of BIM by oncogenic pathways such as the MEK/ERK and PI3K pathways which phosphorylate and inhibit the activity of BIM-EL (Gillings et al., 2009) .
Similarly, variation in NF-kB activity may have contributed to variation in sensitivity to apoptosis by reduction in XIAP and BCL-XL levels as reported elsewhere (Gallagher et al submitted). Induction of p53 dependent BH3 proteins Puma and Noxa did not appear to be involved as their protein levels were unchanged or decreased by treatment with I-BET151, even though mRNA transcripts of Noxa were strongly upregulated at 6 hours in the gene expression arrays. We presume this is a result of rapid degradation of Noxa as described by others (Brinkmann et al., 2013) . The relatively slow kinetics of apoptosis induction (48 hours) are consistent with a model in which apoptosis mediated by BET inhibition requires a number or cascade of transcriptional changes. These changes could include both upregulation of BIM and the disabling of pro-survival signaling provided NF-kB or other as-yet unidentified factors. The slow kinetics could also suggest that the cell must progress through certain stages of the cell 15 cycle to undergo apoptosis, however reduction of G1 arrest by ablating p21 did not increase cell death, providing little support for this hypothesis.
Our analysis of the mechanisms underlying cell cycle arrest was largely consistent with previous studies showing that this appeared to result from upregulation of p21 (Cheng et al., 2013) and in some lines p27. In melanoma lines with upregulation of both p21 and p27, knockdown of p21 reduced G1 arrest suggesting it was the main cell cycle inhibitor. The basis for upregulation of p21 is however not clear. Although p53 was upregulated by I-BET151, knockdown of p53 did not alter G1 arrest (data not shown). This together with the studies on the p53 null Me4405 suggests p53 was not a key transcription factor in cell cycle arrest mediated by I-BET151. CMyc involvement in the cell cycle arrest appeared unlikely in that there was no or minimal downregulation of c-Myc by I-BET151 at the protein or mRNA level.
Knockdown studies of individual BRD proteins suggested that BIM was regulated principally by BRD2. Inexplicably the knockdown of BRD4 was associated with reduced levels of BIM in both cell lines even though apoptosis was increased in both lines. We interpret these findings as indicating that BRD2 may normally suppress BIM whereas BRD4 is part of complexes upregulating BIM. It is possible that following ablation of BRD4 the suppression by BRD2 is unopposed resulting in lower levels of BIM, while I-BET151 treatment also relieves BRD2 suppression and, possibly, activates BIM transcription via other indirect methods. Further studies are needed to see whether a possible feedback mechanism by BRD2 may be involved. As reported elsewhere BRD2 also appeared to be the main protein involved in regulation of NF-kB (Gallagher et al submitted). In contrast, BRD4 appeared to be the major protein involved in cell cycle regulation in melanoma as shown by the siRNA studies, in agreement with reports by others (Segura et al., 2013a) .
These initial studies show that induction of apoptosis may be an important additional mechanism that can be added to effects of BET inhibitors on cell cycle and NF-kB in treatment of cancer.
Further studies are needed to define which transcription factors are involved in upregulation of Our results highlight the potential of using BET inhibitors in combination with other drugs, with BET inhibition priming cells to undergo apoptosis via increased levels of BIM and decreased BCL2, BCL-XL and XIAP. Taken together, the present results provide evidence that I-BET151 has several potential effects against melanoma cells that are independent of known mutational and signal pathway activation and justify further investigation for their use in treatment of melanoma.
Materials and Methods
Cell lines
Human melanoma cell lines Mel-RMU, Sk-Mel-28, Mel-RM, Mel-JD and Me1007 have been described previously (Zhang et al., 1999) . Cells were cultured in Dulbecco's modified Eagle medium (DMEM) containing 10% fetal calf serum (FCS) (AusGeneX, Brisbane, Australia). In addition primary melanoma cell cultures were established as described previously (Nguyen et al., 2001 ) from 2 patients entered into the Roche "BRIM2" phase II study of vemurafenib in patients who had failed previous treatment. The patient lines were established prior to treatment and during relapse from treatment with vemurafenib, labeled "pre" and "post" respectively as described elsewhere (Lai et al., 2012a) . These studies were approved by the Hunter and New England Research Ethics Committee.
Chemicals and transfections.
I-BET151 was supplied by GlaxoSmithKline (Brentford, UK). The caspases were inhibited by addition of 10µM Q-VD-OPH (SM Biochemicals, Anaheim, CA) to medium 3 hours before I- 
q-RT-PCR
RNA was extracted from cell lines using RNeasy Plus mini prep kit (QIAGEN), quantitated using a Nanodrop (Thermo Scientific, Wilmington, DE) and 1µg RNA reverse transcribed with SuperScriptIII (Invitrogen). cDNA was amplified on AB7900 (Applied Biosystems) using Universal PCR Master Mix and Taqman probes (Applied Biosystems) specific for BIM (Hs00708019_s1), p21 (Hs00355782_m1), BRD2 (Hs01121986_g1), BRD3 (Hs00201284_m1), BRD4 (Hs04188087_m1) and normalized to levels of 18S (Hs99999901_s1).
Analysis of cell viability, cell death, cell cycle and mitochondrial membrane potential.
Cell growth assays were performed using CellTiter-Glo (Promega) as described by the manufacturer. Apoptotic cells were quantified using Annexin-V/propidium iodide staining as 
Western blotting
Western blot analysis was carried out as described previously (Irvine et al., 2010) . Antibodies 
Transcriptome analysis
Total RNA was extracted in duplicate from 75cm 2 culture flasks of both "pre" and "post" cell lines from Patient-1 and Patient-3, 6 and 24 hours after cells had been treated with 10 µM I-BET151 or DMSO control. The RNA was isolated using TRIZOL and purified with an RNeasy purification kit (Qiagen) with DNAse I digestion on the column and the RNA quality verified using the Agilent 2100 Bioanalyser (Agilent Technologies, Palo Alto, CA). Gene expression analysis was performed using the HumanHT-12 v4 Expression BeadChip (Illumina, San Diego, CA) and BeadStation system from Illumina. Quality control was performed on all chips using 20 GenomeStudio (Illumina). Data were log2 transformed and quantile normalized following filtering out of unexpressed probesets. Probesets were collapsed to single genes and paired
LimmaGP analysis was performed on all cell lines, comparing DMSO vs. I-BET151 treated cells at either 6 or 24 hour treatment lengths. These results were used to perform Gene Set Enrichment Analysis (GSEA), which identifies if pre-determined sets of genes tend to be upregulated or downregulated, was performed in GenePattern using the Broad Institute database MSigDB. Cell Death % P a t ie n t-3 -p r e P a t ie n t-3 -p o s t P a t ie n t-1 -p r e PMAIP1  STK17B  RHOB  FOXO3  ECT2  KLF11  MAP3K5  PHLDA3  HOXA5  SIRT1  THBS1  PTRH2   IL6  PIM2  DHRS2  NOTCH1  GCLC  PIM1  ASNS  HSPA1A  ZNF16  NUP62  BCL2L2  PLK1  BIRC2  LEF1  BCL2L1  BCL3  CLCF1  WNT5A ANKRD1  RHOB  BNIP3  FAM162A  BCL6  MLLT11   BID  NET1  ECT2  KLF11  AES  SIAH1  MAP3K5  TOP2A  HOXA5  PPP2R4  KCNMA1  TFAP2A  SIRT1  IL6  DHRS2  GCLC  PIM2  THOC6  WFS1  SOD2  CAT  HSPA1A  CCL2  AURKB  SCG2  TMBIM4  VEGFB  BIRC2  PRKCH  FMN2  FHL2  HSPA5  PLK1  BIRC5  NUP62  CRYAB  MAD2L1  ITGA5  SNAI2  SRC  BCL3  VEGFA  CAV1  LEF1  CLCF1 
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